Additionally, sensitivity to carboplatin/cisplatin was associated with the inferred protein activities of CHEK1 and CDK1, which are common markers of triple-negative breast cancer (Fig. 3A; Supplemental Fig. S10B; Heiser et al. 2012). This evidence concerns the gene CDK1 and triple-negative breast carcinoma.